{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Allergic reaction/hypersensitivity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dehydration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Dyspnea (shortness of breath)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Fatigue (asthenia, lethargy, malaise)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Glucose, serum-high (hyperglycemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemorrhage, pulmonary/upper respiratory - Nose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypotension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Inf (clin/microbio) w/Gr 3-4 neuts - Lung"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Inf w/normal ANC or Gr 1-2 neutrophils - Catheter"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Inf w/normal ANC or Gr 1-2 neutrophils - Lung"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Leukocytes (total WBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Memory impairment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Mucositis/stomatitis (functional/symp) - Oral cav"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Muscle weakness, not d/t neuropathy - body/general"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neuropathy: motor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Neuropathy: sensory"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Neutrophils/granulocytes (ANC/AGC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pain - Bone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pain-Other (Specify)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pneumonitis/pulmonary infiltrates"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Rash/desquamation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Rash: acne/acneiform"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Sodium, serum-low (hyponatremia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombosis/thrombus/embolism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Vomiting"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.","groups":[{"description":"Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR.","id":"OG000","title":"Gemcitabine and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"Eligible patients who received any treatment were included in the adverse event summaries. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included.","reportingStatus":"POSTED","timeFrame":"Patients were assessed for adverse events after the first cycle of treatment and then every three months while on treatment.","title":"Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug","type":"SECONDARY","unitOfMeasure":"Participants with a given type of AE"}